首页> 外国专利> ERYTHROPOIETIN AND ANTI-TUMOR NECROSIS FACTOR ALPHA COMBINATION THERAPY

ERYTHROPOIETIN AND ANTI-TUMOR NECROSIS FACTOR ALPHA COMBINATION THERAPY

机译:促红细胞生成素和抗肿瘤坏死因子α联合治疗

摘要

The present invention provides a method to treat anemic and non-anemic subjects having malignancies with a combination of EPO and an anti-Tumor Necrosis Factor compound such that there is a reduced need for transfusion and a greater hemoglobin level. The present invention provides a method to treat anemic and non-anemic subjects having malignancies with a combination of EPO and an anti-Tumor Necrosis Factor compound such that anemia may be successfully prevented or treated during the course of a chemotherapeutic regimen. The present invention provides a method to treat anemic and non-anemic subjects having malignancies with a combination of EPO and an anti-Tumor Necrosis Factor compound such that the patients show greater quality of life, show relief from fatigue symptoms, and show improvement in physical performance and well being.
机译:本发明提供了一种用EPO和抗肿瘤坏死因子化合物的组合治疗具有恶性肿瘤的贫血和非贫血受试者的方法,从而减少了输血需求和更高的血红蛋白水平。本发明提供了一种用EPO和抗肿瘤坏死因子化合物的组合治疗具有恶性肿瘤的贫血和非贫血受试者的方法,从而可以在化学疗法的过程中成功地预防或治疗贫血。本发明提供了一种用EPO和抗肿瘤坏死因子化合物的组合治疗具有恶性肿瘤的贫血和非贫血受试者的方法,从而使患者表现出更高的生活质量,减轻疲劳症状,并且身体状况得到改善性能和幸福感。

著录项

  • 公开/公告号EP1423693A4

    专利类型

  • 公开/公告日2006-06-07

    原文格式PDF

  • 申请/专利权人 ORTHO-MCNEIL PHARMACEUTICAL INC.;

    申请/专利号EP20010959479

  • 发明设计人 ITRI LORETTA;

    申请日2001-08-02

  • 分类号A61K38/18;A61K45;A01K67;A01K67/027;A01K67/033;A01N43/04;A61K31/454;A61K31/52;A61K31/573;A61K31/70;A61K38/17;A61K38/22;A61K39/395;A61K45/06;A61P7/06;A61P35;G01N33;

  • 国家 EP

  • 入库时间 2022-08-21 21:30:26

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号